Here's Why BioCryst Pharmaceuticals Jumped 15% in May

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) increased 15% in May, according to data provided by S&P Global Market Intelligence, as investors jump in ahead of the potential launch of berotralstat as a treatment for hereditary angioedema in the U.S., Japan, and the EU, as well as a readout for galidesivir as a treatment for COVID-19.

Berotralstat is under review by the Food and Drug Administration, with a decision expected on or before Dec. 3. Regulators in Japan are expected to make a decision in the second half of 2020, and a decision from regulators in the EU is expected in early 2021.

A clinical trial for galidesivir is currently under way in Brazil. The study will initially enroll 24 hospitalized patients with COVID-19, testing three different doses of the drug. After that part is complete, the biotech plans to enroll an additional 42 patients testing the best dose found in the first part of the study. 

Continue reading

Source Fool.com